The aetiology of T1D is largely unknown, but it is thought that a genetic predisposition, environmental factors and distinctive metabolic changes are involved in the initiation, development and ...

Cannabis users with type 1 diabetes (T1D) can be misdiagnosed with diabetic gastroparesis on the basis of symptoms or presentation with or without gastric emptying tests; however, cannabinoid ...

Diabetes is one of the leading health concerns in India. with over a million population suffering with this metabolic condition, immediate relief response needs to be undertaken. Type 1 diabetes ...

An IgA anti-transglutaminase 2 (TGA-IgA) antibody cut-off of approximately 6.1 times the upper limit of normal optimised celiac disease diagnosis in children and adolescents with type 1 diabetes ...

Human non-MHC T1D genes on H-2 g7 'diabetes-resistant' backgrounds to understand T1D genotype-phenotype relationships Knockout and overexpression models of specific immunomodulatory pathways for ...

Healthcare (as we know it) is evolving to meet the needs of an increasingly digital world. Between telehealth adoption and people of all ages embracing “health from home” solutions, it’s ...

- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

The University of Bristol's Diabetes and Metabolism Research Group is conducting the T1D-DAB study to explore how age and ethnicity affect the development of Type 1 Diabetes. We know a lot about Type ...

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...

Current standards of care do not address the underlying cause of the disease and leave people with T1D susceptible to both hypo- and hyperglycemia and their associated morbidity and mortality. There ...